Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
82actual
Sites
61
Countries
Bulgaria, Croatia, Czechia +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-23 | actual | When the study began enrolling |
| Primary completion | 2026-03-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
Interventions
- Drug: Tafasitamab — also filed as INCMOR00208, MOR00208
- Drug: Lenalidomide
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR)
measured Approximately 24 months
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed